108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
基于血小板特异性肽的新型类血小板 PLGA-PSP 纳米颗粒可缓解创伤性出血
Authors Fu W, Wei H, Ren D, Zheng Y, Zhang J, Mu S, Yang L
Received 8 May 2025
Accepted for publication 30 August 2025
Published 19 September 2025 Volume 2025:20 Pages 11491—11504
DOI https://doi.org/10.2147/IJN.S539137
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Kamakhya Misra
Wenda Fu, Hua Wei, Dongxia Ren, Yan Zheng, Jin Zhang, Shijie Mu, Longfei Yang
Department of Transfusion Medicine, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi, 710038, People’s Republic of China
Correspondence: Longfei Yang; Email tdyanglf@fmmu.edu.cn Shijie Mu, Email musj1963@fmmu.edu.cn
Background: Platelets play a crucial role in regulating coagulation. However, balancing the supply and clinical demands of platelet concentrates is a tough challenge. It is urgent to explore a novel platelet substitute with biosafety and efficacy in traumatic hemorrhage.
Methods: The platelet-like PLGA-PSP nanoparticles were synthesized by covalently coupling the linear platelet-specific peptides including CBP, VBP and FMP to the active carboxyl functional group of PLGA-PEG nanoparticles. The biosafety of the platelet-like PLGA-PSP nanoparticles was assessed. Subsequently, in vitro experiments were conducted to verify the effects of PLGA-PSP nanoparticles on platelet adhesion, aggregation and activation. Furthermore, the hemostatic efficacy of PLGA-PSP nanoparticles was confirmed in the tail vein, liver and femoral artery hemorrhage of normal and thrombocytopenic mice.
Results: We successfully designed and synthesized the non-toxic PLGA-PSP nanoparticles with specific hemostatic ability that significantly induced platelet adhesion and aggregation without triggering unexpected platelet activation. Moreover, the application of PLGA-PSP nanoparticles was demonstrated to effectively reduce the bleeding time and blood loss in the tail vein, liver and femoral artery of both normal and thrombocytopenic mice.
Conclusion: The novel platelet-like PLGA-PSP nanoparticles present a promising therapeutic option for the rapid hemostasis of traumatic hemorrhage based on the biosafety and efficacy.
Keywords: traumatic hemorrhage, platelet substitute, platelet-specific peptide, PLGA-PSP nanoparticle
Department of Transfusion Medicine, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi, 710038, People’s Republic of China
Correspondence: Longfei Yang; Email tdyanglf@fmmu.edu.cn Shijie Mu, Email musj1963@fmmu.edu.cn
Background: Platelets play a crucial role in regulating coagulation. However, balancing the supply and clinical demands of platelet concentrates is a tough challenge. It is urgent to explore a novel platelet substitute with biosafety and efficacy in traumatic hemorrhage.
Methods: The platelet-like PLGA-PSP nanoparticles were synthesized by covalently coupling the linear platelet-specific peptides including CBP, VBP and FMP to the active carboxyl functional group of PLGA-PEG nanoparticles. The biosafety of the platelet-like PLGA-PSP nanoparticles was assessed. Subsequently, in vitro experiments were conducted to verify the effects of PLGA-PSP nanoparticles on platelet adhesion, aggregation and activation. Furthermore, the hemostatic efficacy of PLGA-PSP nanoparticles was confirmed in the tail vein, liver and femoral artery hemorrhage of normal and thrombocytopenic mice.
Results: We successfully designed and synthesized the non-toxic PLGA-PSP nanoparticles with specific hemostatic ability that significantly induced platelet adhesion and aggregation without triggering unexpected platelet activation. Moreover, the application of PLGA-PSP nanoparticles was demonstrated to effectively reduce the bleeding time and blood loss in the tail vein, liver and femoral artery of both normal and thrombocytopenic mice.
Conclusion: The novel platelet-like PLGA-PSP nanoparticles present a promising therapeutic option for the rapid hemostasis of traumatic hemorrhage based on the biosafety and efficacy.
Keywords: traumatic hemorrhage, platelet substitute, platelet-specific peptide, PLGA-PSP nanoparticle